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Abstract
Background: Transcript dosage imbalance may influence the transcriptome. To gain insight into the role of altered
gene expression in hereditary colorectal polyposis predisposition, in the present study we analyzed absolute and
allele-specific expression (ASE) of adenomatous polyposis coli (APC) and mutY Homolog (MUTYH) genes.
Methods: We analyzed DNA and RNA extracted from peripheral blood mononuclear cells (PBMC) of 49 familial
polyposis patients and 42 healthy blood donors selected according similar gender and age. Patients were studied
for germline alterations in both genes using dHPLC, MLPA and automated sequencing. APC and MUTYH mRNA
expression levels were investigated by quantitative Real-Time PCR (qRT-PCR) analysis using TaqMan assay and by
ASE assays using dHPLC-based primer extension.
Results: Twenty out of 49 patients showed germline mutations: 14 in APC gene and six in MUTYH gene. Twenty-
nine patients did not show mutations in both genes. Results from qRT-PCR indicated that gene expression of both
APC and MUTYH was reduced in patients analyzed. In particular, a significant reduction in APC expression was
observed in patients without APC germline mutation vs control group (P < 0.05) while APC expression in the mutation
carrier patients, although lower compared to control individuals, did not show statistical significance. On the other
hand a significant reduced MUTYH expression was detected in patients with MUTYH mutations vs control group (P <
0.05). Altered ASE of APC was detected in four out of eight APC mutation carriers. In particular one case showed a
complete loss of one allele. Among APC mutation negative cases, 4 out of 13 showed a moderate ASE. ASE of MUTYH
did not show any altered expression in the cases analyzed. Spearman’s Rho Test analysis showed a positive and
significant correlation between APC and MUTYH genes both in cases and in controls (P = 0.020 and P < 0.001).
Conclusions: APC and MUTYH showed a reduced germline expression, not always corresponding to gene mutation.
Expression of APC is decreased in mutation negative cases and this appears to be a promising indicator of FAP
predisposition, while for MUTYH gene, mutation is associated to reduced mRNA expression. This study could
improve the predictive genetic diagnosis of at-risk individuals belonging to families with reduced mRNA expression
regardless of presence of mutation.
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Introduction
Colorectal cancer (CRC) is one of the most frequent
causes of cancer death worldwide [1, 2]. Inherited forms
of CRC account for as much as 20–30 % of all CRC
cases whereas hereditary colorectal polyposis syndromes
account for about 1 % of all cases of CRC [3]. The iden-
tification of mechanisms predisposing to hereditary colo-
rectal polyposis is necessary for direct genetic diagnosis
of carrier status in cases without detectable mutations in
known genes. Mendelian predisposition syndromes, like
familial adenomatous polyposis (FAP), associated with
mutations in known genes account for 5–10 % of the
overall incidence of the disease [4, 5]. The genes mostly
implicated in the inheritance of adenomatous polyposis,
a condition that leads to colorectal cancer, are adenoma-
tous polyposis coli (APC) involved in FAP (OMIM
#175100) and mutY Homolog (MUTYH) involved in
MUTYH-associated polyposis (MAP) (OMIM#608456).
The tumor suppressor APC gene, a component of Wnt
pathway, encodes a multifunctional protein that regu-
lates many cellular processes, as differentiation, prolifer-
ation, life and death decision; it is involved in ephithelial
turn-over, then APC loss is an early event in gut epithe-
lium tumorigenesis [6]. APC germline mutations are de-
tected in the majority of FAP patients, even if in a
relevant subset of cases the mutations cannot be identi-
fied. A fraction (7–23 %) of APC mutation negative
cases with phenotypes overlapping with attenuated FAP
(AFAP) or classical FAP, is associated with biallelic
germline variants of the MUTYH gene. MUTYH to-
gether with OGG1 and MTH1 is a component of DNA
Base Excision Repair (BER) pathway that removes dam-
aged bases generated by reactive oxygen species (ROS),
capable to induce mutations commonly observed in can-
cerogenesis [7–9]. A relevant phenotypic pre-cancerous
variability has been observed in kindred carrying the
same germline mutation and literature data suggest that
gene expression dosage can play a role as a new genetic
mechanism for colorectal cancer susceptibility [10, 11].
The variation in gene expression contributes to pheno-
typic variability, plays an important role in the etiology
of diseases and may affect absolute and allele specific ex-
pression [12–14]. In up to 50 % of polyposis families no
germline mutation is identified and about 10–15 % of
FAP patients could have a reduced APC expression with
similar phenotype to patients with truncating APC mu-
tation [15, 16]. Germline altered allele specific expres-
sion (ASE) is an indicator of genetic imbalances and a
useful marker of predisposition to polyposis and/or colo-
rectal cancer [10, 11, 17–19]. The dosage of the APC
transcripts may modulate the disease resulting in classic
or attenuated phenotype in cases with and without
pathogenic mutations [17, 18, 20–22]. To gain insight in
the correlation between APC and MUTYH mutations
and altered expression, in the present study we investi-
gated the role of dosage imbalance influencing the tran-
scriptome of these two colon cancer-predisposing genes,
performing an analysis of absolute and allele-specific ex-
pression in patients with different degrees of penetrance
of hereditary colorectal disease. We analyzed peripheral
blood mononuclear cells (PBMCs) from patients with
and without mutations and compared the gene expres-
sion with control individuals. Finally, to understand the
interaction between APC and BER pathway, we investi-
gated the possible mutual modulation. This exploratory
study on correlation among mutational spectrum, gene
dosage and phenotype, could improve the genetic diag-
nosis performing predictive testing of at-risk individuals
belonging to families with reduced mRNA expression re-
gardless of presence of mutation. The identification of
carriers of mutation or/and reduced mRNA expression
may be helpful for the appropriate monitoring and clin-
ical management of patients.
Patients and methods
Patients and nucleic acid preparation
We analyzed 49 polyposis patients recruited in different
collaborating Italian Institutions including the Units of
Clinical Physiopathology and Medical Genetics of the
University of Florence, Medical Genetics of the University
“G. d’Annunzio” of Chieti-Pescara, Gastroenterology
and Digestive Endoscopy of the “Regina Elena” National
Cancer Institute of Rome. This series consisted of patients
affected by classical FAP, AFAP, multiple colorectal polyp-
osis (with more than five polyps) [23] and familial colon
cancer. Sixteen cases represented a research-based cohort
from Aceto et al. [24]. Patients were selected based on
availability of RNA and on the presence of at least 2–5
polyps at diagnosis in the probands and/or their relatives.
One hundred and fifty healthy blood donors who reported
no personal or family history of adenomas or colorectal
cancer have been employed to identify and filter tran-
scripts that exhibit altered transcript expression in the un-
affected population. All study participants gave written
informed consent after verbal counseling and the study
was approved by the Ethics Committee of the University
“G.d’Annunzio” of Chieti. Nucleic acids extraction from
PBMCs and synthesis of complementary DNA (cDNA)
from 3.5 μg of total RNA were performed as previously
described [24]. Samples with poor quality or insufficient
quantity of target in the cDNA template were not in-
cluded in the mRNA expression analyses.
Screening for sequence variants
Mutation screening of APC and MUTYH genes for pa-
tients analyzed in previous study was conducted with
different PCR-based techniques as previously described
[24]. Additional screening was conducted in this study
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using denaturing high performance liquid chromatog-
raphy (dHPLC) and automated sequencing. For APC
also multiplex ligation-dependent probe amplification
(MLPA) analysis was performed using the SALSA
P043 APC MLPA kit (MCR-Holland, Amsterdam, The
Netherlands) to detect large gene-rearrangements.
Mutations are listed in the International Society for
Gastrointestinal Hereditary Tumours (InSiGHT, http://
www.insight-group.org/variants/database/) database.
Real-time quantitative PCR analysis (qRT-PCR)
The level of APC and MUTYH messenger RNA (mRNA)
expression in PBMCs was investigated by TaqMan quan-
titative real-time PCR (qRT-PCR) analysis using Ste-
pOne™ 2.0 (Applied Biosystems). Data were analyzed
using the comparative Ct method and were graphically
indicated as 2−ΔCt ± SE. In accordance with the method,
the mRNA amounts of the target genes (APC and
MUTYH #Hs01568269_m1, #Hs01014856_m1 respect-
ively, Applied Biosystems) were normalized to the en-
dogenous housekeeping gene GUSB (#Hs99999908_m1,
Applied Biosystems) [25]. Target and reference genes
were amplified separately in triplicate for both cases and
controls in a volume of 10 μl containing 1 μl template
cDNA diluted 1:10, 0.5 μl of primers and probes mixture
(20X FAM-labeled Assay-on-Demand Gene Expression
Assay Mix) and 5 μl of 2X TaqMan Universal Master
Mix (Applied Biosystems). The cycling conditions were
performed as follows: 2 min at 50 °C, 10 min at 95 °C and
40 cycles of 15 s at 95 °C followed by 1 min at 60 °C.
Allele-specific expression (ASE) analysis
ASE analyses were performed by dHPLC-based single
nucleotide primer extension (SNuPE) [26]. This tech-
nique allows to measure the relative allele expression
comparing the heights of the peaks corresponding to the
two alleles obtained by PCR-amplified gDNA and cDNA
templates. Overall mean ratio obtained by analyzing gDNA
templates for the corresponding variant was used to
normalize cDNAs. These normalized cDNA/gDNA ratios
were designed as ASE values. ASE measures were per-
formed multiple times and coefficient of variation (CV)
was calculated to test for assay reproducibility. Single-
nucleotide polymorphism (SNP) genotyping analysis was
performed to detect allelic markers of heterozygosity use-
ful to ASE analysis. The frequent and common SNPs
rs2229992 (c.1458C > T) (minor allele frequency, MAF =
0.49) in exon 12 of the APC gene and rs3219489
(c.1014G >C) (MAF = 0.31) in exon 12 of MUTYH gene
were selected. An additional specific assay on exon 7 fre-
quent pathogenic mutation of MUTYH gene (rs34612342,
c.536A >G) was also designed (Additional file 1: Table S1).
Statistical analysis
The one-way analysis of variance (ANOVA) in the abso-
lute expression of mRNA levels was performed to test the
difference in means between different groups. Bonferroni
post-hoc test allowed us to identify which group resulted
significantly different based on the comparison of multiple
values simultaneously.
ASE values were summarized as median, mean and
standard deviation (SD) separately for the two groups
(cases and controls). Shapiro-Wilk test was used to
evaluate the normality in the distribution within each
group. To assess differences of ASE values between cases
and controls the Kruskall-Wallis test was performed
followed by other tests carried out to determine if differ-
ent proportions of individuals in cases and controls
group were at a standard distance from the overall mean
(1.0 SD, about 68 % of the distribution) by Chi-square
test or Fisher’s exact test. To assess a possible correl-
ation between the two genes Spearman’s rho correlation
coefficient was evaluated. All analyses were performed
with STATA software (version 10).
Results
Cases were analyzed for APC and MUTYH germline
mutations, absolute expression and ASE. All analyses
were performed and compared to a control population.
Screening for APC and MUTYH germline mutations
Mutation analysis detected pathogenic mutations in 20
patients out of 49 analyzed (Table 1). For APC gene 14
mutations introducing frameshift were detected, of
which 12 previously published [2] and 2 detected in the
present study, including a deletion of entire exon 15 and
the p. Leu878_CysfsX916. Among these mutations only
one (the p.His393_PhefsX396) fell in the gene portion
associated to an attenuated phenotype [8, 21, 27]. This
mutation was found in case GD37, and was located in
the alternative splicing region of exon 10. Mutation ana-
lysis of MUTYH gene was performed for cases negative
at APC mutation screening and detected sequence vari-
ants in six patients: two carriers of heterozygous variants
(GD72 and GD155), three compound heterozygotes
(GD68, GD82#1, GD82#2), and one carrier of exon 12
homozygous deletion (GD91) (Table 1). Four mutations
were detected in a previous study [24] and 2 in the
present study. Twenty-nine out of 49 patients did not
show mutations in both genes (Table 2). Basic clinical
features are reported in Tables 1 and 2; as noted polyp-
osis patients without APC mutations manifested similar
phenotype to patients with truncating APC mutations.
Analyses of APC and MUTYH mRNA expression
Patients analyzed by qRT-PCR belonged to three dif-
ferent subgroups: carriers of APC mutations (APC+,
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n. 13), carriers of MUTYH mutations (MUTYH+, n.
5) and patients negative at mutation screening for
both genes (APC-/MUTYH-, n. 21). 2−ΔCt mean
values of cases were compared to those of 42 healthy
blood donors selected according similar gender and
age in order to have a comparable sample size. RNA
amounts from ten patients were used up for qRT-
PCR analysis.
Analysis of APC gene expression by qRT-PCR
showed a statistically significant reduced expression in
the 21 APC-/MUTYH- patients (mean value of 0.18 ±
0.07 2−ΔCt) as compared to the control group (mean
value of 0.32 ± 0.12 2−ΔCt) (P < 0.05) (Fig. 1a). On the
other hand, APC expression in the 13 APC+ and 5
MUTYH+ patients, although lower compared to control
individuals, did not show statistical significance (Fig. 1a).
Regarding MUTYH gene expression, qRT-PCR analysis
showed a statistically significant reduced expression in the
5 MUTYH+ patients (mean value of 0.17 ± 0.05 2−ΔCt) as
compared to the control group (mean value of 0.56 ± 0.22
2−ΔCt) (P < 0.05), while the 13 APC+ and the 20 APC-/
MUTYH- patients did not show significant MUTYH
Table 1 Clinical and molecular characteristics of patients with mutations





Additional informations APC Mutation Exon Effect
GD22 45 FAP yes (vertical) osteomas, desmoids, duodenal
cancer
c.646-1 G > Ab 7 Criptic splice site
fsX292
GD23 n.a. FAP yes c.4666dupb 16 p.Thr1556_AsnfsX1558
GD31 72 FAP yes (vertical) >1000 polyps, colon cancer c.3183_3187delb 16 p.Lys1061_LysfsX1062
GD33 n.a FAP yes (vertical) c.904 C > Tb 9 p.Arg302X
GD37 41 AFAP yes (vertical) ileal polyps, colon cancer, c.1176_1177insTb 10 p.His393_PhefsX396
GD38 35 FAP yes (vertical) CHRPE, osteomas c.4717 G > Tb 16 p.Glu1573X
GD41 24 FAP yes (vertical) gastric and ileal polyps c.2684 C > Ab 16 p.Ser895X
GD48 33 FAP yes (vertical) duodenal polyps c.2758_2759delb 16 p.Asp920_CysfsX922
GD57 22 FAP no c.2299 C > Tb 16 p.Gln767X
GD58 48 FAP no c.4393_4394delb 16 p.Ser1465_TrpfsX1467
GD59 31 FAP yes (vertical) c.4192_4193delb 16 p.Ser1398_SerfsX1407
GD74 27 FAP yes (vertical) >100 polyps, desmoids, colon
cancer
ex15del 15 Δ 15
GD103 55 FAP no c.694 C > Tb 7 p.Arg232X
GD119 26 FAP yes (vertical) duodenal polyps, rectal cancer c.2633delT 16 p.Leu878_CysfsX916





Additional informations MUTYH Mutation Exon Effect
GD68 45 AFAP no 40 polyps [c.536A > G]+ 7, 12 [p.Tyr179Cys]+
[c.1163 T > C]b [p.Leu388Pro]
GD72 29 FAP yes (vertical) [c.536A > G]
+ [c.=]b
7 [p.Tyr179Cys] + [p.=]
GD82#1 49 Multiple
polyposis
yes (horizontal) caecum cancer [c.536A > G]+ 7, 10 [p.Tyr179Cys]+
[c.820C > T]b [p.Arg274Trp]
GD82#2 54 Colon cancer yes (horizontal) [c.536A > G]+ 7, 10 [p.Tyr179Cys]+
[c.820C > T] [p.Arg274Trp]
GD91 30 Multiple
polyposis
no 100 polyps [c.1145del]+ 12 [p.Ala382AlafsX407]+
[c.1145del]b [p.Ala382AlafsX407]
GD155 70 AFAP no [c.536A > G]
+ [c.=]
7 [p.Tyr179Cys] + [p.=]
aIdentification number is followed by number of individual if several members were investigated per family
bData from [24]
n.a. = not available
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reduction (Fig. 1b). One case, GD117, resulted not in-
formative by MUTYH qRT-PCR (Additional file 1: Table
S1).
Altogether, these data suggest that reduced APC ex-
pression may be detected even in the absence of APC
germline mutation and that MUTYH mutations may be
associated with reduced MUTYH expression.
ASE analysis of APC and MUTYH genes
Germline ASE of APC was performed in 20 (out of 49)
cases heterozygous for the SNP rs2229992 (c.1458C > T),
of which 7 carrying APC mutation (Additional file 1:
Table S1). To investigate if variations in ASE values can
contribute to forms of colorectal disease with different
degree of penetrance, the values were compared to data
obtained from 53 consecutive CRC patients previously
analyzed by the same assay [11]. We included one CRC
case (case 19) turned out to be a de novo FAP in previ-
ous study, among APC mutation positive cases. A total
of 21 polyposis and 52 consecutive CRC patients, were
compared to 68 previously analyzed control individuals
[11]. Results of ASE analysis showed in one case,
GD41, bearing the p.Ser895X mutation, a germline al-
lelic loss. The mean and median values are reported in
Table 3, excluding the case GD41 without a quantifiable
ASE value. The distribution of ASE values was tested
for normality (Shapiro-Wilk normality test) and both
APC mutation-positive and -negative FAP cases were
distributed normally (respectively P = 0.499 and 0.682),
whereas CRC cases and controls were not (Table 3).
Only APC mutation-negative FAP cases had median
and mean ASE values slightly, but significantly lower
Table 2 Clinical and molecular characteristics of patients without mutations
Patients without APC and MUTYH mutations
Casea Age at diagnosis Phenotype Family History (transmission) Additional informations
GD70 43 AFAP yes (vertical)
GD78 35 Multiple polyposis yes (vertical) >10 polyps
GD80 45 Multiple polyposis yes (horizontal)
GD81 36 AFAP yes (vertical)
GD83 36 FAP yes (horizontal)
GD84 32 FAP no desmoids
GD86 17 FAP yes (vertical) 143 microadenomas and 2 polyps
GD87 22 FAP no rectal polyps, desmoids
GD92 58 AFAP n.a.
GD94 65 AFAP yes (vertical) 5 polyps, colon cancer
GD102 n.a. Multiple polyposis n.a. cystadenocarcinoma (unknown site)
GD106 50 Multiple polyposis n.a.
GD107 42 Multiple polyposis yes (horizontal)
GD109 52 Multiple polyposis no 36 polyps, colon cancer
GD112#1 37 FAP yes (vertical) colon, gastric, duodenal and rectal polyps
GD112#2 14 FAP yes (vertical) colon and gastric polyps
GD117 63 Multiple polyposis yes (horizontal) 10 polyps, gastric cancer
GD118 71 AFAP yes (vertical) 10 polyps, colon cancer
GD121 41 AFAP n.a.
GD122 59 Colon cancer yes (vertical)
GD123 60 AFAP no colon cancer
GD140 37 AFAP no gastric polyps
GD146 44 AFAP no colon and breast cancer
GD153 47 AFAP yes (horizontal) hyperplastic polyps, colon cancer
GD154 44 FAP no 836 polyps
GD157 53 FAP no colon cancer
GD158 52 FAP yes (vertical)
GD159 26 FAP yes (vertical) rectal cancer
GD160 52 AFAP no 10 polyps
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than controls by Kruskal-Wallis test (Table 3). Four out
of 8 APC mutation-positive cases showed an imbal-
anced ASE, with values more than 1 SD from the over-
all mean (<0.99 and >1.53) compared to controls
(Table 4; P = 0.022). Furthermore the group of the CRC
cases deviating more than 1 SD from the overall mean
was significantly larger than controls (Table 4; P =
0.001), as noted before [11]. Altogether, as regards APC
mRNA expression, four patients with imbalanced ASE
(GD22, GD41, GD72, GD82#1) showed also low levels of
APC expression by qRT-PCR (Additional file 1: Table S1).
As regards MUTYH, all APC negative cases, heterozy-
gous at MUTYH c.1014G > C variant, and cases bearing
the c.536A > G (Y179C) pathogenic variant, were ana-
lyzed for ASE using 2 primer extension assays developed
in this study. The ASE assay for MUTYH c.1014G > C
variant was performed in 14 out of 49 cases (Additional
file 1: Table S1) and 34 control individuals resulted het-
erozygous for the variant. The ASE assay for MUTYH
c.536A > G (Y179C) pathogenic variant was performed
in 5 cases (Additional file 1: Table S1). One case (GD68)
has been analysed for both MUTYH assays. Considering
that the means of ASE assays using the c.1014G > C and
the c.536A > G variants were very similar (CV 4.28 % of
the two means) we calculated the overall mean of all ASE
values measured in cases and controls with both assays
and that was 0.96 (SD ± 0.14; CV 14.51 %); the range of
variation ± 1 SD was <0.82 and >1.10 (Additional file 2:
Tables S2 and Additional file 3: Table S3). There were
slight differences in mean and median ASE values in cases
and controls. None of the individuals showed monoallelic
Fig. 1 Germline expression by qRT-PCR of the APC and MUTYH genes. The figure shows the results from qRT-PCR analysis conducted in 39 patients
carrying either APC mutation, MUTYH mutation or none mutations in both genes, compared to 42 controls. mRNA isolated from PBMCs was quantified
by qRT-PCR using GUSB gene as endogenous control. Data were analyzed using the comparative Ct method and are expressed as mean and standard
error (SE) of relative expression, which corresponds to the 2−ΔCt value; *P < 0.05 versus control group with post hoc test. a Relative expression levels of
APC gene and associated table showing 2−ΔCt mean values ± SE of each subgroup. b Relative expression levels of MUTYH gene and associated table
showing 2−ΔCt mean values ± SE of each subgroup
Table 3 Mean and Median ASE values of cases and controls for
APC c.1458C > T assay
Status N Mean
(±SD)





























aCase GD41 was not considered in the table because it showed monoallelic
expression
bPreviously published [11]
Bold values indicate statistical significance
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expression or marked ASE. Results from MUTYH ASE
analysis showed modest imbalances of values deviating
more than 1 SD from the mean, in several individuals
among cases and controls, but the differences were not
statistical (Additional file 3: Table S3).
We also correlated the APC and MUTYH gene expres-
sion in 39 cases and 42 controls by Spearman’s test. As
reported in Fig. 2, the two genes were positively corre-
lated both in cases and in controls (respectively Rho =
0.381, P = 0.020 e Rho = 0.708, P < 0.001). This correl-
ation was more strengthened among controls.
Discussion
In this study we analyzed mutational status, transcript
dosage and disease phenotype, to investigate the role of
altered gene expression in the pathogenesis of familial
colorectal tumors. The results of this study showed that
at germline level gene expression of both APC and
MUTYH was reduced in hereditary colorectal polyposis
patients compared to healthy donors. In particular a re-
duced APC expression was observed even in patients
without APC germline mutation meanwhile a reduced
MUTYH expression has been detected in patients with
MUTYH mutations. The statistically significant reduction
in APC expression detected by qRT-PCR in 21 cases with
APC-/MUTYH- genotype (Fig. 1a) is in agreement with
previous studies [16, 28]. As far as ASE of APC, marked
imbalances (>2fold) were detected only in two APC+ pa-
tients included in this study. Other patients had only
modest degrees of imbalances of APC, which, as previ-
ously discussed, increase the risk of colorectal cancer [11].
Among the 14 cases that could be analyzed by both qRT-
PCR and ASE, 6 showed no altered expression by both
methods, 4 (GD22, GD41, GD72, GD82#1) showed re-
duced expression and altered ASE, 2 showed (GD68,
GD84) reduced expression by qRT-PCR with a balanced
allelic expression, likely related to decreased expression of
both alleles, and 2 had only modest degrees of imbalanced
expression which might reflect a small reduction in the
expression of one allele compensated by a small increase
in the expression of the other (GD33, GD123) (Additional
file 1: Table S1, Additional file 3: Table S3). A noteworthy
observation comes from the allelic expression analysis of
case GD41, carrier of the p.Ser895X APC mutation. In this
case ASE identified the complete loss of an allele that
could not be seen with the simple observation by qRT-
PCR even if this case, with monoallelic expression, showed
an approximately 50 % reduction in the overall expression
of APC (Additional file 1: Table S1). Among patients with
MUTYH+ genotype two cases, GD82#1 and GD82#2, be-
longing to the same family, compound heterozygotes and
carriers of the same mutations, showed different levels of
APC expression (Table 1, Additional file 1: Table S1).
GD82#1, affected by multiple polyposis and ciecum car-
cinoma, showed a lower level of APC expression; for
GD82#2, presenting colorectal carcinoma without polyp-
osis, the expression level for APC gene was higher. It can
be assumed that the difference in APC expression in the
two affected brothers might be associated with their differ-
ent phenotype.
The cause of mRNA reduced expression is not known
and could be related to mutations in regions of the gene
not analyzed by mutational screening. Because APC is
an oncosuppressor with a dominant pattern of hereditary
Fig. 2 Correlation between APC and MUTYH gene expression. The figure shows APC and MUTYH absolute mRNA expression values measured in
39 cases (left) and 42 controls (right) correlated by Spearman’s test: correlation coefficient (rho) and P values (p)
Table 4 Distribution of cases and controls at 1.0 SD from the
overall mean ASE for APC c.1458C > T assay








Controlsb 57 11 68
APC + polyposis cases 4 4a 8 0.022
APC - polyposis cases 9 4 13 0.214
CRC casesb 30 22 52 0.001
Overall 100 41 141
aCase GD41, with monoallelic expression, was included in the table among
cases deviating more than 1.0 SD from the overall mean
bPreviously published [11]
Bold values indicate statistical significance
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transmission, its decreased expression is expected to con-
tribute to FAP predisposition in these mutation negative
cases. Thus decreased expression of APC in mutation
negative cases appears to be a promising indicator of FAP
predisposition.
Regarding MUTYH, five out of six patients with muta-
tions, analyzed by qRT-PCR, showed a statistically re-
duced expression of the MUTYH gene and four out of
five were carriers of MUTYH Y179C mutation. Patients
belonging to this group manifested an attenuated pheno-
type (with absence of family history or horizontal trans-
mission), except case GD72, who developed a classical
FAP with vertical transmission (Table 1); these findings
are in line with several studies [9, 27, 29].
Case GD72, carrier of a monoallelic Y179C mutation
and showing by qRT-PCR a reduced expression (0.06 ±
0.01, Additional file 1: Table S1), has been analyzed by
ASE of MUTYH and APC genes. In MUTYH the two al-
leles showed a quantitatively similar expression (1.08); as
regarding APC, we found a moderately reduced relative
expression (0.83) (Additional file 1: Table S1). In this pa-
tient both MUTYH alleles showed a low but equal ex-
pression with a reduction in absolute mRNA expression.
This might explain FAP phenotype in a carrier of mono-
allelic MUTYH mutation. It is noteworthy that case
GD72 manifested the disease at the age of 29 years. Indi-
viduals carrying monoallelic mutations tend to have a
later presentation of disease of at least 5 years compared
to biallelic ones but patients with heterozygous Y179C
mutation have usually a more severe phenotype with
earlier onset as compared with the other frequent
G396D mutation [9, 30]. The missense Y179C mutation,
situated in the catalytic domain of MUTYH, led to the
formation of an inactive protein, as it can remove nor-
mal interactions with other proteins [31] and causes a
quantitative reduction of mRNA, which would lead to
reduced protein levels. Further studies on protein in those
cases with both mutations and reduced expression could
support our data on MUTYH protein functionality.
The risk of colorectal cancer in heterozygous carriers
of MUTYH mutations has been considered comparable
with that of first-degree relatives of patients with sporadic
colorectal cancer by some authors [32] or considered in-
creased due to a synergism with alterations in other genes
involved in BER or other reparative pathways [9, 33].
Other authors assume that a slightly increased risk of can-
cer related to the presence of a monoallelic inactivation of
MUTYH could be attributed to a situation of haploinsuffi-
ciency [34]. A complete picture of the effect of monoallelic
mutations on the variability of clinical phenotype linked
to MUTYH is still to be defined. Studies of absolute and
relative gene expression applied to a larger group of
monoallelic mutation carriers could provide a clue of pos-
sible involved pathways.
Correlation between germline altered gene expression
and disease, sometimes in absence of mutations, have
been reported in chronic inflammatory diseases and in
forms of intellectual disability, all compared to control
individuals [35–37]. In spite of several evidences that
showed as different phenotypes can be classified based
on degree of severity of polyposis and site of APC gene
mutation [8, 21, 27, 38, 39], there is a scarcity of data
concerning correlations between disease manifestations
and APC germline reduced expression. The observations
in relatives GD82#1 and GD82#2 might be the first evi-
dence of this kind of correlations. It will be very interest-
ing to extend the study to other polyposis families with a
larger number of relatives. If confirmed in further stud-
ies, the correlation between germline reduced expression
and disease manifestations could improve the predictive
genetic diagnosis of at-risk individuals belonging to fam-
ilies with reduced mRNA expression regardless of pres-
ence of mutation.
Among the various cellular functions of APC gene, it
was recently discovered its involvement in DNA repair
mediated by BER, as it is able to modulate the activity of
this pathway [40]. Therefore we searched for possible
mutual modulation between APC and MUTYH expres-
sion in 39 cases and 42 controls by Spearman’s test. As
reported in Fig. 2, the two genes were positively
correlated both in cases and in controls although the
significance seemed to be stronger among controls. A
modulation between APC and MUTYH was also ob-
served in Fig. 1: carriers of mutation compared to
cases without mutations in one gene showed a higher
expression of the other gene.
Conclusions
In this study the most significant result comes from the
analysis of APC and MUTYH expression levels in her-
editary colorectal polyposis patients carrying either APC
mutation, MUTYH mutation or none mutations in both
genes, compared to 42 controls. Both genes showed a re-
duced germline expression, not always corresponding to
gene mutation. Expression of APC is decreased in muta-
tion negative cases and this appears to be a promising
indicator of FAP predisposition, while for MUTYH gene,
reduced mRNA expression is associated to mutation.
This is the first evidence of ASE analysis of MUTYH
but, as the recessive pattern of hereditary transmission
of this gene, altered ASE could be masked by contem-
porary reduced expression of both alleles. This study
could improve the predictive genetic diagnosis of at-risk
individuals belonging to families with reduced mRNA
expression regardless of presence of mutation. It will be
very interesting to extend the study to other genes of the
Wnt and BER pathways or to other known cancer pre-
disposing genes.
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